AcelRx wins U.S. patents for pain treatment
(Reuters) - AcelRx Pharmaceuticals said the U.S. patent office granted two patents on the specialty pharmaceutical company's methods for managing post-operative pain.
AcelRx said the notice of allowance from the U.S. Patent and Trademark Office could provide protection to its NanoTab technology for delivering a pain drug, sufentanil, till at least Feb, 2029.
A Notice of Allowance is issued after the USPTO decides that a patent can be granted after a company has applied for one.
AcelRx's shares closed at $3.40 on Tuesday on the Nasdaq.
(Reporting by Balaji Sridharan in Bangalore; Editing by Saumyadeb Chakrabarty)
- Flights delayed as air pollution hits record in Shanghai
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- French launch Central African Republic mission but deaths mount
- Supreme Court to decide on patent protections for software
Nelson Mandela: 1918 - 2013
Reuters looks at the life and times of Nelson Mandela, an icon of peace and reconciliation who came to embody the struggle for justice around the world. Video